Surgical Site Infection Clinical Trial
— DVNOfficial title:
Acute Kidney Injury During Daptomycin Versus Vancomycin Treatment in Cardiovascular Critically Ill Patients: a Propensity Score Matched Analysis
Verified date | May 2019 |
Source | University Hospital, Montpellier |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Observational |
Acute kidney injury (AKI) is a frequent complication that occurs in 15 to 25% of patients
after vascular surgery, and up to 40% of patients after cardiac surgery. AKI compromises
seriously short and long-term prognosis of critically ill patients. Several AKI risk factors
have been identified including a chronic pathology of the patient such as kidney failure or
diabetes, acute kidney injury related to hemodynamic disorders during surgery, including
cardiopulmonary bypass, or sepsis, and the use of nephrotoxic agents such as some
antibiotics, colloids or iodine contrast agents. Avoiding nephrotoxic agents is therefore
strongly recommended in ICU patients, to reduce the incidence of AKI, or to reduce its
severity.
The aim of this cohort study was to assess whether the use of daptomycin, was associated to a
lower incidence of AKI than vancomycin in cardiovascular ICU patients, with similar efficacy.
This is a retrospective observational study with a propensity score adjustment to reduce the
bias of selection for a comparative analysis between two antibacterial treatments used in
routine care.
Since treatments were not randomized, the investigators used the propensity score method for
primary endpoint analysis. For this, the investigators included the covariates potentially
related to treatment and outcome in a multivariate logistic model explaining the choice of
treatment. This propensity score was used in the second model as an adjustment covariate
included in the multivariate analysis to determine factors independently associated with the
primary endpoint (AKI within 7 days).
The main hypothesis is the first line antibiotic treatment with daptomycin leads to less
nephrotoxicity than vancomycin in a population known at high risk for AKI and with at least a
similar efficacy on clinical success rate.
Status | Completed |
Enrollment | 72 |
Est. completion date | January 30, 2016 |
Est. primary completion date | January 30, 2016 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility |
Inclusion criteria: - Patient older than 18 years - Admitted in ICU from January 2010 to December 2012 - Suspected or proven cardiac, vascular or profound surgical site infection with Gram-positive cocci (GPC) methicillin-resistant (MR) strains (including probabilistic treatment for patients with acquisition of MR risk factors) - Treatment duration greater than or equal to 48 hours (at least 2 doses of daptomycin administered or 2 days of vancomycin infusion) - Antibiotic treatment started in peri-operative (from 48 hours before the onset of surgery) or in postoperative period (during ICU stay) Exclusion criteria: - Prophylaxis indication of antibiotics - Kidney disease on chronic dialysis - Acute onset of RRT before initiation of DAP or VAN treatment - Staphylococcus pneumonia |
Country | Name | City | State |
---|---|---|---|
France | Uh Montpellier | Montpellier |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Montpellier |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Incidence of Acute Kidney Injury (AKI) | AKI stade 1, 2 or 3 according to KDIGO definition with baseline creatinine given by the last creatinine value before the start of treatment | 7 days after the treatment initiation | |
Secondary | Incidence of Acute Kidney Injury (AKI) | AKI stade 1, 2 or 3 according to KDIGO definition with baseline creatinine given by the last creatinine value before the start of treatment | 14 days after the treatment initiation | |
Secondary | Maximal decrease of glomerular filtration rate (GFR) | Decrease of GFR, estimated by CKD-EPI formula, from baseline as measured by all serum creatinine determinations during treatment | Through study treatment completion, an average of 2 weeks | |
Secondary | Incidence of severe renal failure | AKI stade 2 or 3 according to KDIGO definition or decrease of GFR more than 50% from baseline | Through study treatment completion, an average of 2 weeks | |
Secondary | Incidence of renal replacement therapy (RRT) | RRT initiated between the first and the last treatment administrations | Through study treatment completion, an average of 2 weeks | |
Secondary | Duration of RRT | Number of days between the first RRT initiation and the end of the last RRT during the ICU stay (excluding RRT performed in a dialysis center for chronic renal failure) | Through study completion limited to ICU stay, an average of 2 weeks | |
Secondary | Incidence of clinical treatment failure | defined by either persistent positive cultures, worsening of clinical status, death due to initial infection, or relapse after the end of treatment. It was assessed in case of documented GPC infection | 15 days after the end of treatment | |
Secondary | Incidence of premature discontinuation of treatment | defined as a treatment stopped because of adverse event or clinical failure except death | Through study treatment completion, an average of 2 weeks | |
Secondary | Mortality | all cause mortality | 28 days after treatment initiation | |
Secondary | Mortality | all cause mortality | 6 months (180 days) after treatment initiation |
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT04096885 -
The Inselspital Surgical Cohort Study
|
||
Terminated |
NCT03820648 -
Wound Protector Dual-ring Alexis® in Pancreaticoduodenectomy
|
N/A | |
Completed |
NCT04067843 -
Effect of Photodynamic Treatment on Skin Microbiome. Single Center Study
|
N/A | |
Terminated |
NCT04042077 -
Delafloxacin IV and OS Administration Compared to Best Available Therapy in Patients With Surgical Site Infections
|
Phase 3 | |
Completed |
NCT05841576 -
Anaesthetic Management Guided by COMET Measurements
|
N/A | |
Withdrawn |
NCT05338281 -
NPWT for Abdominal Incisions in DIEP Reconstructions: A RCT
|
N/A | |
Recruiting |
NCT03042091 -
Neomycin and Metronidazole Hydrochloride With or Without Polyethylene Glycol in Reducing Infection in Patients Undergoing Elective Colorectal Surgery
|
Early Phase 1 | |
Completed |
NCT01697748 -
Prospective Study on Cesarean Wound Outcomes
|
N/A | |
Terminated |
NCT01789697 -
Text Message Study
|
N/A | |
Recruiting |
NCT05966961 -
Novosyn® CHD vs Polyglactin 910 Suture to Close Wounds After Emergency or Elective Laparotomy or Laparoscopic Surgery
|
||
Recruiting |
NCT05077592 -
Addition of Pre-wound Closure Povidone Iodine Wash Versus Direct Wound Closure Effect on Surgical Site Infections
|
Phase 4 | |
Recruiting |
NCT05502380 -
Broad-spectrum Antibiotic Prophylaxis in Tumor and Infected Orthopedic Surgery
|
Phase 3 | |
Recruiting |
NCT05763602 -
PVI to Prevent S. Aureus SSI After Fixation of HELEF (POTENT Study)
|
Phase 4 | |
Recruiting |
NCT03221023 -
Intrawound Vancomycin Prophylaxis for Neural Stimulator
|
Phase 2/Phase 3 | |
Completed |
NCT03257202 -
Topical Treatment and Prevalence of P. Acnes
|
Phase 2 | |
Completed |
NCT06154720 -
Surgical Site Infection After Episiotomy Repair Related to Routine Use of Antibiotic Prophylaxis in Low-Risk Population
|
||
Not yet recruiting |
NCT06465901 -
A Stratified, Multi-ARm, muLti-site Randomised Platform Trial Aiming to Reduce the INcidence of Post-operative SSI
|
N/A | |
Not yet recruiting |
NCT04820075 -
Efficacy of an Intervention to Improve the Preoperative Shower in Scheduled Surgery
|
N/A | |
Recruiting |
NCT03561376 -
Zinc Oxide Versus Petrolatum Following Skin Surgery
|
Early Phase 1 | |
Not yet recruiting |
NCT04496180 -
Prevena to Prevent Surgical Site Infection After Emergency Abdominal Laparotomy
|
N/A |